Boston Scientific Corp. (NYSE:BSX) officials said today that renewed strength in its drug-eluting stent business should be enough to offset a weak cardiac rhythm management market over the near term.
Speaking at an investors conference in Boston this morning, BSX officials said they expect the U.S. CRM market to be soft for at least the next six months, due in part to a massive study released in January showing that doctors implant defibrillators in thousands of patients who don’t need them.